Track ZyVersa Therapeutics Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

ZyVersa Therapeutics Inc. Common Stock ZVSA · Stock Open ZyVersa Therapeutics Inc. Common Stock in new tab

0.0990 USD
Add to portfolio
P/E
0.00
EPS
-3.67
P/B
-0.06
ROE
-112.65
Beta
0.87
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateNov. 18, 2026
P/E0.00
EPS-3.67
Book Value-1.75
Price to Book-0.06
% Insiders0.024%
Estimates
Forward P/E-0.02
Forward EPS-4.80

DCF Valuation

Tweak assumptions to recompute fair value for ZyVersa Therapeutics Inc. Common Stock (ZVSA)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

ZyVersa Therapeutics Inc. Common Stock Logo ZyVersa Therapeutics Inc. Common Stock Analysis (ZVSA)

United States Health Care Official Website Stock

Is ZyVersa Therapeutics Inc. Common Stock a good investment? ZyVersa Therapeutics Inc. Common Stock (ZVSA) is currently trading at 0.0990 USD.

In terms of valuation, the stock trades at a P/E ratio of 0.00. This relatively low multiple may signal that ZyVersa Therapeutics Inc. Common Stock is undervalued compared to historical market norms.

Earnings Schedule: ZyVersa Therapeutics Inc. Common Stock is expected to release its next earnings report on Nov. 18, 2026. The market consensus estimate for Forward EPS is -4.80.

Investor FAQ

Does ZyVersa Therapeutics Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is ZyVersa Therapeutics Inc. Common Stock?

ZyVersa Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Nov. 18, 2026. The company currently has a trailing EPS of -3.67.

Company Profile

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial for the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100 a humanized monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of numerous inflammatory diseases, with cardiometabolic conditions associated with obesity as the lead. The company has a license agreement with L&F Research LLC, and InflamaCORE, LLC. ZyVersa Therapeutics, Inc. was founded in 2014 and is based in Weston, Florida.

Exchange Ticker
NMS (United States) ZVSA
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Dec. 5, 2023 0.03
April 26, 2024 1:10
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion